Research map: Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors

Back to the article

Papers in this map

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes · Bernard Zinman · 2015 · 12293 citations · Cited by this paper
  2. The aftermath of alcohol misuse: Linking cellular damage, suboptimal micronutrient nutrition, and organ dysfunction · 2026 · Related
  3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes · Bruce Charles Neal · 2017 · 7911 citations · Cited by this paper
  4. A dive into the untapped potential of marine compounds in counteracting neurodegeneration · 2026 · Related
  5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  6. Mathematical modeling of T cell exhaustion in the tumor microenvironment · 2026 · Related
  7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes · Stephen D. Wiviott · 2018 · 6475 citations · Cited by this paper
  8. C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy · 2026 · Related
  9. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy · Vlado Perkovic · 2019 · 6222 citations · Cited by this paper
  10. Circular RNA serves as an upstream regulator of the miRNA//ABCC1 axis in human cancers · 2026 · Related
  11. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis · Pontus Boström · 2012 · 4830 citations · Cited by this paper
  12. Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk · 2026 · Related
  13. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes · Christoph Wanner · 2016 · 3687 citations · Cited by this paper
  14. Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders · 2026 · Related
  15. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association · Sheri R. Colberg · 2016 · 3012 citations · Cited by this paper
  16. Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review · 2025 · Related
  17. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development · Hyun Mi Kang · 2014 · 1584 citations · Cited by this paper
  18. Dapagliflozin attenuates lipotoxic tenocyte injury via PPARα activation and irisin-driven antioxidant pathways · 2025 · Related
  19. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes · Christopher Paul Cannon · 2020 · 1533 citations · Cited by this paper
  20. SGLT2 Inhibitors as Mitochondrial Therapies in Heart Failure: A Bioenergetic Revolution in Cardiometabolic Medicine · 2026 · Related
  21. Exercise Induces Hippocampal BDNF through a PGC-1α/FNDC5 Pathway · Christiane D. Wrann · 2013 · 1441 citations · Cited by this paper
  22. Targeting integrin pathways: mechanisms and advances in therapy · Xiaocong Pang · 2023 · 1289 citations · Cited by this paper
  23. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients · Ele Ferrannini · 2014 · 1145 citations · Cited by this paper
  24. Physical activity, exercise, and chronic diseases: A brief review · Elizabeth Anderson · 2019 · 1021 citations · Cited by this paper
  25. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review · Subodh Verma · 2018 · 1002 citations · Cited by this paper
  26. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis · Ele Ferrannini · 2016 · 993 citations · Cited by this paper
  27. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models · Mychael V. Lourenco · 2018 · 969 citations · Cited by this paper
  28. Mitochondrial dysfunction in pathophysiology of heart failure · Bo Zhou · 2018 · 951 citations · Cited by this paper
  29. Integrin signalling at a glance · David S. Harburger · 2008 · 916 citations · Cited by this paper
  30. Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes · Hiddo J.L. Heerspink · 2013 · 839 citations · Cited by this paper
  31. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes · Ele Ferrannini · 2016 · 731 citations · Cited by this paper
  32. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial · Ofri Mosenzon · 2019 · 686 citations · Cited by this paper
  33. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits · Antonius Baartscheer · 2016 · 671 citations · Cited by this paper
  34. Physiology and role of irisin in glucose homeostasis · Nikolaos Perakakis · 2017 · 644 citations · Cited by this paper
  35. Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors · Hyeonwoo Kim · 2018 · 641 citations · Cited by this paper
  36. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation · Laween Uthman · 2017 · 616 citations · Cited by this paper
  37. Renal Gluconeogenesis · John E. Gerich · 2001 · 610 citations · Cited by this paper
  38. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart · Chenguang Li · 2019 · 600 citations · Cited by this paper
  39. The effects of acute and chronic exercise on PGC ‐1α, irisin and browning of subcutaneous adipose tissue in humans · Frode Norheim · 2013 · 570 citations · Cited by this paper

Source: OpenAlex (CC0)